Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study

Neurobiology of Aging

Volumn 31, Issue 3, 2010, Pages 447-463

  Kumakura, Yoshitaka ^a,b   Vernaleken, Ingo ^c   Buchholz, Hans Georg ^d   Borghammer, Per ^a   Danielsen, Erik ^a   Gründer, Gerhard ^c   Heinz, Andreas ^e   Bartenstein, Peter ^d,f   Cumming, Paul ^a,f  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF TOKYO   (Japan)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aging; Dopamine; FDOPA; MAO; PET; Storage; Vesicles

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; DRUG METABOLITE; FLUORODOPAMINE F 18; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; CYTOSOL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STEADY STATE;

ADULT; AGED; AGING; BRAIN; CEREBRAL CORTEX; CORPUS STRIATUM; DOPA DECARBOXYLASE; DOPAMINE; HUMANS; KINETICS; MALE; MIDDLE AGED; MODELS, NEUROLOGICAL; POSITRON-EMISSION TOMOGRAPHY; YOUNG ADULT;

EID: 74149084314     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.05.005     Document Type: Article

References (82)

1. Amirjani N., Ashworth N.L., Gordon T., Edwards D.C., and Chan K.M. Normative values and the effects of age, gender, and handedness on the Moberg pick-up test. Muscle Nerve 35 6 (2007) 788-792
2. Arai R., Karasawa N., Geffard M., and Nagatsu I. l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci. Lett. 195 (1995) 195-198
3. Behnke, S., Double, K.L., Duma, S., Broe, G.A., Guenther, V., Becker, G., Halliday, G.M., 2007. Substantia nigra echomorphology in the healthy very old: Correlation with motor slowing, 34(3) 1054-1059.
4. Berg D., Siefker C., Ruprecht-Dörfler P., and Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 56 1 (2001) 13-17
5. Blomqvist G. On the construction of functional maps in positron emission tomography. J. Cereb. Blood Flow Metab. 4 (1984) 629-632
6. Borghammer P., Kumakura Y., and Cumming P. [Letter] Fluorodopa F18 positron emission tomography studies and the progression of Parkinson's disease. Arch. Neurol. 62 (2005) 1480
7. Brown W.D., Taylor M.D., Roberts A.D., Aokes T.R., Schueller M.J., Holden J.E., Malischke L.M., DeJesus O.T., and Nickles R.J. FluoroDOPA PET shows nondopaminergic as well as dopaminergic destinations of levodopa. Neurology 53 (1999) 1212-1218
8. Bunzeck, N., Schütze, H., Stallforth, S., Kaufmann, J., Düzel, S., Heinze, H.J., Düzel, E., 2007. Mesolimbic novelty processing in older adults. Cereb. Cortex, March 23 (Epub ahead of print).
9. Collignon A., Maes F., Delaere D., Vandermeulen D., Suetens P., and Marchal G. In: Bizais Y., Barillot C., and Di Paola R. (Eds). Automated Multimodality Image Registration based on Information Theory" Information Processing in Medical Imaging (1995), Kluwer Academic Publishers, Dordrecht 263-274
10. Crone C. The permeability of capillaries in various organs as determined by use of the 'indicator diffusion' method. Acta Physiol. Scand. 58 (1963) 292-305
11. Cumming P., and Gjedde A. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms. Synapse 29 (1998) 37-61
12. 18F]-6-fluoro-l-3,4-dihydroxyphenylalanine in the hooded rat. J. Neurochem. 48 (1987) 601-608
13. Cumming P., Brown E., Damsma G., and Fibiger H.C. Formation and clearance of interstitial metabolites of dopamine and serotonin in rat striatum: an in vivo microdialysis study. J. Neurochem. 59 (1992) 1905-1914
14. 18F]FDOPA) in humans. J. Cereb. Blood Flow Metab. 13 (1993) 668-675
15. Cumming P., Kuwabara H., Ase A., and Gjedde A. Regulation of DOPA decarboxylase in brain of living rat. J. Neurochem. 65 (1994) 1381-1390
16. 18F]DOPA) metabolism in the rat. J. Neurochem. 63 (1994) 1675-1682
17. 3H]DOPA in the telencephalon of living rat. Brain Res. 747 (1997) 60-69
18. Cumming P., Munk O.L., and Doudet D. Loss of metabolites from monkey striatum during positron emission tomography with FDOPA. Synapse 41 (2001) 212-218
19. Cordes M., Snow B.J., Cooper S., Schulzer M., Pate B.D., Ruth T.J., and Calne D.B. Age-dependent decline of nigrostriatal dopaminergic function: a positron emission tomographic study of grandparents and their grandchildren. Ann. Neurol. 36 4 (1994) 667-670
20. Dagher A., Bleicher C., Aston J.A., Gunn R.N., Clarke P.B., and Cumming P. Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers. Synapse 42 (2001) 48-53
21. Danielsen E.H., Smith D.F., Gee A.D., Venkatachalam T.K., Hansen S.B., Hermansen F., Gjedde A., and Cumming P. Cerebral 6-[(18)F]fluoro-l-DOPA (FDOPA) metabolism in pig studied by positron emission tomography. Synapse 33 (1999) 247-258
22. 18F]fluorodopamine in vivo. J. Neurosci. Methods 76 (1997) 157-165
23. 3H]DOPA in living rat brain investigated by compartmental modelling of static autoradiograms. J. Neurosci. Methods 78 (1997) 157-168
24. Dejesus O.T., Endres C.J., Shelton S.E., Nickles R.J., and Holden J.E. Noninvasive assessment of aromatic l-amino acid decarboxylase activity in aging rhesus monkey brain in vivo. Synapse 39 1 (2001) 58-63
25. Dhawan V., Ishikawa T., Patlak C., Chaly T., Robeson W., Belakhlef A., Margouleff C., Mandel F., and Eidelberg D. Combined FDOPA and 3OMFD PET studies in Parkinson's disease. J. Nucl. Med. 37 (1996) 209-216
26. Doudet D.J., Rosa-Neto P., Munk O.L., Ruth T.J., Jivan S., and Cumming P. Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study. Neuroimage 30 (2006) 26-35
27. Eberling J.L., Roberts J.A., Taylor S.E., VanBrocklin H.F., O'Neil J.P., and Nordahl T.E. No effect of age and estrogen on aromatic l-amino acid decarboxylase activity in rhesus monkey brain. Neurobiol. Aging 23 3 (2002) 479-483
28. Eidelberg D., Takikawa S., Dhawan V., Chaly T., Robeson W., Dahl R., Margouleff D., Moeller J.R., Patlak C.S., and Fahn S. Striatal 18F-dopa uptake: absence of an aging effect. J. Cereb. Blood Flow Metab. 13 5 (1993) 881-888
29. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., Shea C., Alexoff D., MacGregor R.R., Schlyer D.J., Zezulkova I., and Wolf A.P. Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 14065-14069
30. Fowler J.S., Logan J., Volkow N.D., Wang G.J., MacGregor R.R., and Ding Y.S. Monoamine oxidase: radiotracer development and human studies (Review). Methods 27 (2002) 263-277
31. Frey K.A., Koeppe R.A., Kilbourne M.R., Vander Borght T.M., Albin R.L., Gilman S., and Kumar D.E. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann. Neurol. 40 (1996) 873-884
32. Gillings N.M., Bender D., Falborg L., Marthi K., Munk O.L., and Cumming P. Kinetics of the metabolism of four PET radioligands in living minipigs. Nucl. Med. Biol. 28 (2001) 97-104
33. Gjedde A. High- and low-affinity transport of d-glucose from blood to brain. J. Neurochem. 36 (1981) 1463-1471
34. Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res. 257 (1982) 237-274
35. Gjedde A., Reith J., Dyve S., Léger G., Guttman M., Diksic M., Evans A., and Kuwabara H. Dopa decarboxylase activity of the living human brain. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 2721-2725
36. Gjedde A., Léger G., Cumming P., Yasuhara Y., Evans A., Guttman M., and Kuwabara H. Striatal l-DOPA decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis. J. Neurochem. 61 (1993) 1538-1541
37. Gozlan H., Daval G., Verge D., Spampinato U., Fattaccini C.M., Gallissot M.C., el Mestikawy S., and Hamon M. Aging associated changes in serotoninergic and dopaminergic pre- and postsynaptic neurochemical markers in the rat brain. Neurobiol. Aging 11 (1990) 437-449
38. Gründer G., Vernaleken I., Muller M.J., Davids E., Heydari N., Buchholz H.G., Bartenstein P., Munk O.L., Stoeter P., Wong D.F., Gjedde A., and Cumming P. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28 4 (2003) 787-794
39. Hartvig P., Lindner K.J., Tedroff J., Andersson Y., Bjurling P., and Langstrom B. Brain kinetics of 11 C-labelled l-tryptophan and 5-hydroxy-l-tryptophan in the rhesus monkey. A study using positron emission tomography. J. Neural Transm. Gen. Sect. 88 (1992) 1-10
40. 2/3 receptor availability: a combined FDOPA and DMFP PET study in detoxified alcoholics. Am. J. Psychiatry 162 (2005) 1515-1520
41. Hilker R., Schweitzer K., Coburger S., Ghaemi M., Weisenbach S., Jacobs A.H., Rudolf J., Herholz K., and Heiss W.D. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch. Neurol. 62 3 (2005) 378-382
42. Holden J.E., Doudet D., Endres C.J., Chan G.L., Morrison K.S., Vingerhoets F.J., Snow B.J., Pate B.D., Sossi V., Buckley K.R., and Ruth T.J. Graphical analysis of 6-fluoro-l-dopa trapping: effect of inhibition of catechol-O-methyltransferase. J. Nucl. Med. 38 (1997) 1568-1574
43. 18F]fluoro-dopa in human positron emission tomographic studies. J. Cereb. Blood Flow Metab. 11 (1991) 898-913
44. Kish S.J., Shannak K.S., Rajput A.H., Gilbert J.J., and Hornykiewicz O. Cerebellar norepinephrine in patients with Parkinson's disease and control subjects. Arch. Neurol. 41 (1984) 612-614
45. Kish S.J., Shannak K., Rajput A., Deck J.H., and Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J. Neurochem. 58 (1992) 642-648
46. Kish S., Zhong X.H., Hornykiewicz O., and Haycock J.W. Striatal 3,4-dihydroxyphenylalanine decarboxlase in aging: disparity between post-mortem and positron emission tomography studies. Ann. Neurol. 38 (1995) 260-264
47. 18F]fluorodopa to brain of normal volunteers and patients with Parkinson's disease: effect of levodopa. Acta Neurol. Scand. 110 (2004) 188-195
48. 18F]fluorodopamine storage capacity. J. Cereb. Blood Flow Metab. 25 (2005) 807-819
49. Kumakura Y., Gjedde A.H., Danielsen E.H., Christensen S., and Cumming P. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease; correlation with asymmetry of motor symptoms. J. Cereb. Blood Flow Metab. 26 (2006) 358-370
50. 18F]FDOPA/PET study. J. Neurosci. 27 30 (2007) 8080-8087
51. 18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects. J. Cereb. Blood Flow Metab. 13 (1993) 43-56
52. Laakso A., Vilkman H., Bergman J., Haaparanta M., Solin O., Syvälahti E., Salokangas R.K., and Hietala J. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol. Psychiatry 52 7 (2002) 759-763
53. Lavalaye J., Booij J., Reneman L., Habraken J.B., and van Royen E.A. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur. J. Nucl. Med. 27 (2000) 867-869
54. Lee C.S., Samii A., Sossi V., Ruth T.J., Schultzer M., Holden J.E., Wudel J., Pal P.K., de la Fuente-Fernandez R., Calne D.B., and Stoessl J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic nerve terminals in Parkinson's disease. Ann. Neurol. 47 (2000) 493-503
55. 18F]fluorodopa: implications for compartmental modelling and clinical usefulness. Synapse 30 (1998) 351-361
56. Leigland L.A., Schulz L.E., and Janowsky J.S. Age related changes in emotional memory. Neurobiol. Aging 25 8 (2004) 1117-1124
57. Martin W.R., Palmer M.R., Patlak C.S., and Calne D.B. Nigrostriatal function in humans studied with positron emission tomography. Ann. Neurol. 26 (1989) 535-542
58. 2 receptor parameter measurements in ventral striatum. J. Cereb. Blood Flow Metab. 21 (2001) 1034-1057
59. Mikhailova O.N., Gulyaeva L.F., and Filipenko M.L. Gene expression of drug metabolizing enzymes in adult and aged mouse liver: a modulation by immobilization stress. Toxicology 210 (2005) 189-196
60. Ota M., Yasuno F., Ito H., Seki C., Nozaki S., Asada T., and Suhara T. Age-related decline of dopamine synthesis in the living human brain measured by positron emission tomography with l-[beta-11C]DOPA. Life Sci. 79 8 (2006) 730-736
61. Patlak C.S., and Blasberg R.G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab. 5 (1985) 584-590
62. Patlak C.S., Blasberg R.G., and Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3 (1983) 1-7
63. Pifl C., and Hornykiewicz O. Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochem. Int. 49 (2006) 519-524
64. Rao K., Nagendra S.N., and Subhash M.N. Monoamine oxidase isoenzymes in rat brain: differential changes during postnatal development but not aging. Neurobiol. Aging 16 (1995) 833-836
65. Renkin E.M. Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscles. Am. J. Physiol. 197 (1959) 1205-1210
66. Roggeveen A.B., Prime D.J., and Ward L.M. Lateralized readiness potentials reveal motor slowing in the aging brain. J. Gerontol. B: Psychol. Sci. Soc. Sci. 62 2 (2007) P78-84
67. Ruprecht-Dörfler P., Berg D., Tucha O., Benz P., Meier-Meitinger M., Alders G.L., Lange K.W., and Becker G. Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. Neuroimage 18 2 (2003) 416-422
68. Sawle G.V., Colebatch J.G., Shah A., Brooks D.J., Marsden C.D., and Frackowiak R.S. Striatal function in normal aging: implications for Parkinson's disease. Ann. Neurol. 28 6 (1990) 799-804
69. Sossi V., Doudet D.J., and Holden J.E. A reversible tracer analysis approach to the study of effective dopamine turnover. J. Cereb. Blood Flow Metab. 21 (2001) 469-476
70. 18F-fluorodopa data. J. Cereb. Blood Flow Metab. 22 (2002) 232-239
71. i. J. Cereb. Blood Flow Metab. 23 (2003) 301-309
72. Sossi V., de la Fuente-Fernandez R., Holden J.E., Schulzer M., Ruth T.J., and Stoessl J. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J. Cereb Blood Flow Metab. 24 (2004) 869-876
73. Sossi V., de la Fuente-Fernandez R., Schulzer M., Adams J., and Stoessl J. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 129 Pt 4 (2006) 1050-1058
74. Sossi V., de la Fuente-Fernández R., Schulzer M., Troiano A.R., Ruth T.J., and Stoessl A.J. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann. Neurol. 62 (2007) 468-474
75. Stark A.K., and Pakkenberg B. Histological changes of the dopaminergic nigrostriatal system in aging [Review]. Cell Tissue Res. 318 (2004) 81-92
76. Stout D.B., Huang S.C., Namavari M., Satyamurthy N., Yee R.E., and Barrio J.R. Distribution volume of 3-O-methyl-6. J. Cereb. Blood Flow Metab. 20 (2000) 1717-1724
77. Torstenson, R., 1999. Functional regulation of the dopaminergic system in vivo: experimental and clinical studies with positron emission tomography (Comprehensive Summaries... from the Faculty of Pharmacy, 203) (Paperback) Publisher, Uppsala Universitet (December 1999).
78. 18F]fluorodopa (FDOPA) kinetics in brain of healthy volunteers after acute haloperidol challenge. Neuroimage 30 (2006) 1332-1339
79. Volkow N.D., Ding Y.S., Fowler J.S., Wang G.J., Logan J., Gatley S.J., Hitzemann R., Smith G., Fields S.D., and Gur R. Dopamine transporters decrease with age. J. Nucl. Med. 37 (1996) 554-559
80. 18F-N-methylspiroperidol. Psychiatry Res. 67 (1996) 11-16
81. Woods R.P., Cherry S.R., and Mazziotta J.C. Rapid automated algorithm for aligning and reslicing PET images. J. Comput. Assist. Tomogr. 16 (1992) 620-633
82. Wright C.I., Wedig M.M., Williams D., Rauch S.L., and Albert M.S. Novel fearful faces activate the amygdala in healthy young and elderly adults. Neurobiol. Aging 27 2 (2006) 361-374